PSORIASIS VS MALIGNANCIES: POSSIBLE INTERRELATION AND POTENTIAL RISKS


Cite item

Full Text

Abstract

To date one of the most discussed problems in the context of psoriasis is the possibility of correlation between the psoriatic process, considering its systemic nature, and the risk of cancer developing. Such interrelation can be caused both by systemic chronic inflammatory process and by methods of therapy. The purpose of this literature review is to assess the risk of developing malignant neoplasms of various organs and systems, as well as the factors that determine it, in patients with psoriasis in comparison with the general population. The mechanisms of action as well as early and remote side effects of the current treatment are described. The literature data on the risk of their carcinogenic effects are presented. The results of studies of a number of other factors acting as possible initiators of carcinogenesis in patients with psoriasis are highlighted, among them: the presence of a systemic inflammatory reaction, the severity and duration of the course of the disease, and also the comorbid states.

About the authors

A. V Osina

Central State Medical Academy Management of Affairs of the President Russian Federation

Moscow, 121359, Russian Federation

E. S Ponich

Central State Medical Academy Management of Affairs of the President Russian Federation

Moscow, 121359, Russian Federation

Larisa S. Kruglova

Central State Medical Academy Management of Affairs of the President Russian Federation

Email: kruglovals@mail.ru
MD, PhD, professor, Central State Medical Academy Management of Affairs of the President Russian Federation, Moscow, 121359, Russian Federation. Moscow, 121359, Russian Federation

References

  1. Круглова Л.С., Понич Е.С., Михайлова А.А. Применение метотрексата и УФВ 311нм фототерапии у пациентов с тяжелыми формами псориаза, получающих биологическую терапию. Кремлевская медицина. 2016; 4: 55-62
  2. Kimball A.B., Gladman D., Gelfand J.M., Gordon K., Horn E.J., Korman N.J., et al.; National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J. Am. Acad. Dermatol. 2008; 58(6): 1031-42.
  3. Gelfand J.M., Shin D.B., Neimann A.L., Wang X., Margolis D.J., Troxel A.B. The risk of lymphoma in patients with psoriasis. J. Invest. Dermatol. 2006; 126(10): 2194-201.
  4. Boffetta P., Gridley G., Lindelof B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J. Invest. Dermatol. 2001; 117(6): 1531-7.
  5. Brauchli Y.B., Jick S.S., Miret M., Meier C.R. Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. J. Invest. Dermatol. 2009; 129(11): 2604-12.
  6. Hannuksela-Svahn A., Pukkala E., Läärä E., Poikolainen K., Karvonen J. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J. Invest. Dermatol. 2000; 114(3): 587-90.
  7. Jeffes E.W., McCullough J.L., Pittelkow M.R., McCormick A., Almanzor J., Liu G., et al. Methotrexate therapy of psoriasis: differencial sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J. Invest. Dermatol. 1995; 104(2): 183-8.
  8. Ji J., Shu X., Sundquist K., Sundquist J., Hemminki K. Cancer risk in hospitalised psoriasis patients: a followup study in Sweden. Br. J. Cancer. 2009; 100(9): 1499-502.
  9. Olsen J.H., Frentz G., Møller H. Psoriasis and cancer. Ugeskr. Laeger. 1993; 155(35): 2687-91. (in Danish)
  10. Ovcina-Kurtovic N., Kasumagic-Halilovic E. Serum levels of total immunoglobulin E in patients with psoriasis: relationship with clinical type of disease. Med. Arh. 2010; 64(1): 28-9.
  11. Потекаев Н.Н., Круглова Л.С. Псориатическая болезнь. М.: МДВ; 2014.
  12. Соколовский Е.В., Круглова Л.С., Понич Е.С. «Болевые» точки системной терапии биологическими препаратами при псориазе. Российский журнал кожных и венерических болезней. 2015; 18(6): 32-8.
  13. Cai Y., Fleming C., Yan J. New insights of T cells in the pathogenesis of psoriasis. Cell. Mol. Immunol. 2012; 9(4): 302-9.
  14. Raju S.S. Psoriasis and lasting implications. Expert Rev. Clin. Immunol. 2014; 10(2): 175-7.
  15. Baker B.S., ed. Recent advances in psoriasis: the role of the immune system. Imperial College Press; 2000.
  16. Richetta A.G., Mattozzi C., Salvi M., Giancristoforo S., D’epiro S., Milana B., et al. CD4+ CD25+ T-regulatory cells in psoriasis. Correlation between their numbers and biologics-induced clinical improvement. Eur. J. Dermatol. 2011; 21(3): 344-8.
  17. Azarsiz E., Ertam I., Karaca N., Aksu G., Alper S., Kutukculer N. IgG-anti-IgA antibodies: an autoimmune finding in patients with psoriasis vulgaris. Minerva Med. 2012; 103(3): 183-7.
  18. Quatresooz P., Hermanns-Lê T., Pierard G.E., Humbert P., Delvenne P., Piérard-Franchimont C. Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL-23 axis: a primer. J. Biomed. Biotechnol. 2012; 2012: 147413. doi: 10.1155/2012/147413.
  19. Frentz G., Olsen J.H. Malignant tumours and psoriasis: a follow-up study. Br. J. Dermatol. 1999; 140(2): 237-42.
  20. Vlcek F., Mikulikova D. The effect of methotrexate on activity of T-lymphocyte marcer enzymes in patients with psoriasis vulgaris. Bratisl. Lek. Listy. 1995; 96(3): 137-40.
  21. Kurd S.K., Richardson S.K., Gelfand J.M. Update on the epidemiology and systemic treatment of psoriasis. Expert. Rev. Clin. Immunol. 2007; 3(2): 171-85. doi: 10.1586/1744666X.3.2.171.
  22. Menter A., Korman N.J., Elmets C.A., Feldman S.R., Gelfand J.M., Gordon K.B., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J. Am. Acad. Dermatol. 2009; 61(3): 451-85.
  23. Lee J.S., Yun S.J., Lee J.B., Kim S.J., Won Y.H., Lee S.C. The efficacy of cyclosporin in patients with atopic dermatitis. Korean J. Dermatol. 2008; 46(2): 224-30.
  24. Correia S.S., Boraso R.Z., Silva Jr.H.T., Almeida F.A. Ciclosporina no tratamento do pênfigo vulgar. An Bras Dermatol. 1993; 68: 291-3.
  25. Askling J., Fahrbach K., Nordstrom B., Ross S., Schmid C.H., Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol. Drug Saf. 2011; 20(2): 119-30.
  26. Curtis J.R., Singh J.A. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin. Ther. 2011; 33(6): 679-707.
  27. Singh J.A., Wells G.A., Christensen R., Ghogomu E.T., Maxwell L., MacDonald J.K., et al. Adverse effects of biologics: a network meta analysis and Cochrane overview (Review). Cochr. Database Syst. Rev. 2011; 16(2): CD008794.
  28. Понич Е.С., Круглова Л.С., Корчажкина Н.Б. Фотодинамическая и системная биологическая терапия тяжелых форм псориаза. Физиотерапия, бальнеология и реабилитация. 2015; 14(6): 17-20
  29. Young A.R. Photochemotherapy and skin carcinogenesis: a critical review. In: Young A.R., Hönigsmann H., Jori G., eds. The fundamental bases of phototherapy. Milano: OEMF; 1996: 77-87.
  30. Bui J.D., Uppaluri R., Hsieh C.S., Schreiber R.D. Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res. 2006; 66(14): 7301-9.
  31. Dunn G.P., Old L.J., Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004; 21(2): 137-48.
  32. Nakachi K., Hayashi T., Imai K., Kusunoki Y. Perspectives on cancer immuno-epidemiology. Cancer Sci. 2004; 95(12): 921-9.
  33. Pinedo-Vega J.L., Castañeda-López R., Dávila-Rangel J.I., Mireles-García F., Ríos Martínez C., López-Saucedo A. Skin cancer incidence in Zacatecas. Rev. Med. Inst. Mex. Seguro Soc. 2014; 52(3): 282-9. (in Spanish)
  34. Chen Y.J., Wu C.Y., Chen T.J., Shen J.L., Chu S.Y., Wang C.B., Chang Y.T. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan. J. Am. Acad. Dermatol. 2011; 65(1): 84-91.
  35. Stern R.S., Bagheri S., Nichols K.; PUVA Follow-Up Study. The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis. J. Am. Acad. Dermatol. 2002; 47(1): 33-9.
  36. Lim J.L., Stern R.S. High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients. J. Invest. Dermatol. 2005; 124(3): 505-13.
  37. Lee E., Koo J., Berger T. UVB phototherapy and skin cancer risk: a review of the literature. Inter. J. Dermatol. 2005; 44(5): 355-60.
  38. Brauchli Y.B., Jick S.S., Miret M., Meier C.R. Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. J. Invest. Dermatol. 2009; 129(11): 2604-12.
  39. Naldi L., Mercuri S.R. Epidemiology of comorbidities in psoriasis. Dermatol. Ther. 2010; 23(2): 114-8.
  40. Gottlieb A.B., Chao C., Dann F. Psoriasis comorbidities. J. Dermatol. Treat. 2008; 19(1): 5-21.
  41. Reddy S.P., Martires K., Wu J.J. The risk of melanoma and hematologic cancers in patients with psoriasis. J. Am. Acad. Dermatol. 2017; 76(4): 639-47.e2. doi: 10.1016/j.jaad.2016.09.047.
  42. Stern R.S., Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. Cancer. 1994; 73(11): 2759-64.
  43. Stern R.S.; PUVA Follow-Up Study. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J. Am. Acad. Dermatol. 2012; 66(4): 553-62.
  44. Marcil I., Stern R.S. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet. 2001; 358(9287): 1042-5.
  45. Paul C.F., Ho V.C., McGeown C., Christophers E., Schmidtmann B., Guillaume J.C., et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J. Invest. Dermatol. 2003; 120(2): 211-6.
  46. Ji J., Shu X., Sundquist K., Sundquist J., Hemminki K. Cancer risk in hospitalized psoriasis patients: a follow-up study in Sweden. Br. J. Cancer. 2009; 100(9): 1499-502.
  47. Hannuksela-Svahn A., Sigurgeirsson B., Pukkala E., Lindelof B., Berne B., Hannuksela Mo, et al. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. Br. J. Dermatol. 1999; 141(3): 497-501.
  48. Hannuksela-Svahn A., Pukkala E., Laara E., Poikolainen K., Karvonen J. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J. Invest. Dermatol. 2000; 114(3): 587-90.
  49. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006; 295(19): 2275-85.
  50. Bongartz T., Warren F.C., Mines D., Matteson E.L., Abrams K.R., Sutton A.J. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann. Rheum. Dis. 2009; 68(7): 1177-83.
  51. Leombruno J.P., Einarson T.R., Keystone E.C. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann. Rheum. Dis. 2009; 68(7): 1136-45.
  52. Dommasch E.D., Abuabara K., Shin D.B., Nguyen J., Troxel A.B., Gelfand J.M. The risk of infection and malignancy with tumor necrosis factor antagonists in adult patients with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J. Am. Acad. Dermatol. 2011; 64(6): 1035-50.
  53. Asgari M.M., Ray G.T., Geier J.L., Quesenberry C.P. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population. J. Am. Acad. Dermatol. 2017; 76(4): 632-8. doi: 10.1016/j.jaad.2016.10.006.
  54. Lee M.S., Lin R.Y., Chang Y.T., Lai M.S. The risk of developing non-melanoma skin cancer, lymphoma and melanoma in patients with psoriasis in Taiwan: a 10-year, population-based cohort study. Int. J. Dermatol. 2012; 51(12): 1454-60.
  55. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature. 2008; 454(7203): 436-44. doi: 10.1038/nature07205.
  56. Krishnamoorthy S., Honn K.V. Inflammation and disease progression. Cancer Metastasis Rev. 2006; 25(3): 481-91.
  57. Solinas G., Germano G., Mantovani A., Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol. 2009; 86(5): 1065-73.
  58. Zamarron B.F., Chen W.J. Dual roles of immune cells and cells their factors in cancer development and progression. Int. J. Biol. Sci. 2011; 7(5): 651-8.
  59. Pastuła A., Marcinkiewicz J. Myeloid-derived suppressor cells: a double-edged sword? Int. J. Exp. Pathol. 2011; 92(2): 73-8.
  60. Alexandrescu D.T., Riordan N.H., Ichim T.E., Kauffman C.L., Kabigting F., Dutton C.T., Dasanu C.A. On the missing link between inflammation and cancer. Dermatol. Online J. 2011; 17(1): 10.
  61. Suga M., Iyonaga K., Ichiyasu H., Saita N., Yamasaki H., Ando M. Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases. Eur. Respir. J. 1999; 14(2): 376-82.
  62. Бакулев А.Л., Шагова Ю.В., Козлова И.В. Псориаз как системная патология. Саратовский научно-медицинский журнал. 2008; 4(1): 13-20.
  63. Мурашкин Н.Н. Оценка эффективности супрессивной терапии тяжелых форм псориаза у детей. Педиатрическая фармакология. 2007; 4(5): 48-53.
  64. Дранник Т.Н. Клиническая иммунология и аллергология. М.: МИА; 2003.

Copyright (c) 2017 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies